ArkBio Advances Ziresovir Trials for Critically Ill RSV Infants

RSV remains the primary cause of lower respiratory tract infections in young children, resulting in roughly 3.6 million annual hospitalizations and over 100,000 deaths globally. Current medical protocols for severe cases are restricted to supportive care, such as oxygen therapy, as no RSV-specific antiviral has yet received global regulatory approval for this patient demographic. The upcoming multicenter, randomized, double-blind study will assess the drug's efficacy in reducing oxygen dependency and accelerating recovery times for the most vulnerable infants.

Ziresovir, also known as AK0529, previously demonstrated success in phase III trials involving patients aged 1 to 24 months in China. Findings published in The New England Journal of Medicine and The Lancet Child & Adolescent Health indicated that the drug effectively lowers viral loads and decreases the risk of recurrent wheezing and asthma over a two-year period. Following its inclusion in the 2025 WHO Paediatric Drug Optimization publication, this FDA-sanctioned trial serves as a pivotal step toward validating the treatment for clinical use in the most severe, high-risk cases.